Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Core Insights - Standard BioTools Inc. reported preliminary and unaudited revenue results for the full year 2025, expecting combined company revenue of approximately $185 million and revenue from continuing operations of approximately $85 million [1] - The fourth quarter 2025 is projected to have combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million [1] Financial Performance - The CEO of Standard BioTools, Michael Egholm, stated that the company's 2025 performance exceeded guidance and expectations for both combined and continuing operations [2] - The company is on a path toward profitability, having taken actions to streamline operations and improve cost structure, resulting in a leaner organization [2] Strategic Outlook - The sale of SomaLogic to Illumina is expected to close in the first half of 2026, with the company anticipating approximately $550 million in cash post-transaction [2] - The company aims to pursue disciplined mergers and acquisitions to build a diversified leader in life sciences, supported by an experienced team and a simplified operational footprint [2] Company Overview - Standard BioTools Inc. specializes in next-generation technologies that assist biomedical researchers in developing better medicines faster, focusing on areas such as oncology, immunology, and immunotherapy [4]